What is the recommended work‑up for amyloidosis in a young adult to differentiate AL from ATTR type?

Workup for Amyloidosis in Young Adults: Differentiating AL from ATTR

In a young adult with suspected cardiac amyloidosis, you must simultaneously assess for both AL and ATTR amyloidosis through a dual-pathway approach: obtain serum free light chains (sFLC), serum and urine immunofixation electrophoresis (SIFE/UIFE), and bone marrow biopsy to evaluate for AL amyloidosis, while performing cardiac imaging (echocardiography or CMR) followed by 99mTc-PYP/DPD/HMDP scintigraphy if imaging is suggestive—but only proceed with definitive ATTR diagnosis via scintigraphy if the monoclonal protein screen is completely negative 1, 2.

Critical First Steps: Rule Out AL Amyloidosis

The diagnostic algorithm prioritizes excluding AL amyloidosis because:

• AL amyloidosis requires tissue diagnosis AND demonstration of plasma cell dyscrasia 2
• Unlike ATTR, AL cannot be diagnosed non-invasively
• Treatment pathways differ dramatically (chemotherapy vs. TTR-targeted therapy)

Mandatory AL Workup Components:

1. Complete monoclonal protein screen 2:

   • Serum free light chains (sFLC)
   • Serum immunofixation electrophoresis (SIFE)
   • Urine immunofixation electrophoresis (UIFE)
   • Do NOT use SPEP/UPEP alone—insufficient sensitivity 2

2. Tissue biopsy with typing 1, 2:

   • Abdominal fat pad aspiration (84% sensitivity for AL-CM) OR bone marrow biopsy (69% sensitivity) as initial surrogate site
   • If negative and suspicion remains high, proceed to affected organ biopsy
   • Mass spectrometry (LC-MS/MS) is gold standard for typing (88% sensitivity, 96% specificity) 2
   • Immunohistochemistry alone is insufficient, especially with concurrent MGUS

3. Bone marrow biopsy 2:

   • Demonstrates clonal plasma cell proliferation
   • Essential to confirm AL diagnosis even with positive tissue amyloid

Cardiac Imaging to Establish Amyloid Involvement

Typical Imaging Features (Any ONE is sufficient) 1:

Echocardiography:

• LV wall thickness >12 mm
• Relative apical sparing (apical LS/[mid+basal LS] >1)
• Grade ≥2 diastolic dysfunction

Cardiac MRI:

• LV wall thickness above upper limit of normal
• Global ECV >0.40
• Diffuse late gadolinium enhancement (LGE)
• Abnormal gadolinium kinetics (myocardial nulling before blood pool)

Key Differentiating Feature: Transmural LGE patterns strongly suggest ATTR over AL (90% of ATTR vs. 37% of AL show transmural LGE; right ventricular LGE in 100% ATTR vs. 72% AL) 3. However, this distinction requires confirmation, not assumption.

ATTR Diagnosis Pathway (Only After Excluding AL)

ATTR can be diagnosed non-invasively ONLY when ALL three criteria are met 1:

1. 99mTc-PYP/DPD/HMDP Grade 2 or 3 myocardial uptake AND
2. Complete absence of monoclonal protein (negative sFLC, SIFE, UIFE) AND
3. Typical cardiac imaging features (as above)

Critical Pitfall to Avoid:

If ANY abnormality exists on monoclonal protein screening (including MGUS), positive scintigraphy does NOT confirm ATTR 1. In this scenario:

• Refer to specialist amyloid center
• Consider endomyocardial biopsy with mass spectrometry typing
• Over 10% of patients with monoclonal gammopathy can have ATTR deposits 2

Genetic Testing for ATTRv

In young adults, hereditary ATTR (ATTRv) is more likely than wild-type:

• DNA sequencing of all 4 exons of TTR gene if ATTR is confirmed 4
• Age of onset varies by mutation type
• Phenotype may include polyneuropathy, cardiomyopathy, or both 5

Clinical Red Flags Suggesting AL vs. ATTR

AL amyloidosis clues 2:

• Macroglossia
• Periorbital ecchymoses
• Acquired factor X deficiency with coagulopathy
• Unexplained proteinuria
• Hepatomegaly

ATTR amyloidosis clues 1, 6:

• Bilateral carpal tunnel syndrome (without rheumatoid arthritis/trauma)
• Biceps tendon rupture (without trauma)
• Spinal stenosis
• Predominantly cardiac symptoms

Real-World Implementation Gap

Recent data shows only 17% of patients undergo complete monoclonal protein testing before diagnosis 7. This is inadequate. The dual-pathway approach must be systematic:

• 42% of AL patients and 40% of ATTR patients received incomplete workups 7
• Cardiac specialists and general medicine providers order these tests most frequently
• Incomplete testing delays diagnosis and appropriate treatment initiation

When to Perform Endomyocardial Biopsy

Mandatory scenarios 1:

• Equivocal 99mTc-PYP/DPD/HMDP scan results
• Positive scintigraphy WITH any monoclonal protein abnormality
• Suspected concomitant AL and ATTR amyloidosis
• Negative surrogate site biopsies with persistent high clinical suspicion

The biopsy must include Congo red staining with apple-green birefringence under polarized light, followed by mass spectrometry typing 1, 2.